Vansteenkiste 2002.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 320, small cell lung cancer (limited and extensive), and non‐small lung cancer (stage I‐IV); concomitant treatment: chemotherapy
Interventions	drug = Darbepoetin alpha dose = 2.25 mg/kg sc weekly hb‐target = 13‐14 g/dL (women), 13‐15 g/dL (men) planned ESA duration = 12 weeks
Outcomes	Primary: transfusion; secondary: Hb response, Hb, transfusion timing and quantity, QoL
Notes	study number = 49684
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	based on a schedule specified by Amgen before the start of the study
Allocation concealment?	Low risk	central randomization